What Is Waskyra, and Why Does It Matter? Waskyra (etuvetidigene autotemcel) is a new gene therapy approved to treat Wiskott-Aldrich syndrome (WAS), a rare inherited condition that affects the immune ...
The U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel) as the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). RCCS San Raffaele ...
Italian non-profit organization Fondazione Telethon today announced the European Commission’s decision of January 9, to grant ...
2025 would also go down in history as the year when gene therapies began to go mainstream, with multiple of them being approved, writes Satyen K. Bordoloi My first memory of cancer is the younger ...
Fondazione Telethon announces the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation in ...
Fondazione Telethon announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra, an ex vivo gene therapy for patients with Wiskott ...
AGC Biologics receives US and EU marketing approvals for Waskyra to treat Wiskott-Aldrich syndrome: Milan Thursday, January 22, 2026, 14:00 Hrs [IST] With the decision by the US F ...
Robin Alderman faces an agonizing reality: Gene therapy might cure her son Camden’s rare, inherited immune deficiency. But it’s not available to him. In 2022, London-based Orchard Therapeutics stopped ...
This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approvedMILAN--(BUSINESS WIRE)--#CGT--With the decision by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results